Toward a Paradigm Shift in the Therapeutic Approach to Fuchs Endothelial Corneal Dystrophy

Over the past decade, Descemet membrane endothelial keratoplasty (DMEK) has become the standard for the treatment of endothelial diseases, with Fuchs endothelial corneal dystrophy (FECD) being the most common indication. Descemet membrane endothelial keratoplasty in eyes with FECD usually results in successful clinical outcomes with low postoperative complication rates. Because of the fast and reliable visual rehabilitation after DMEK, the visual threshold for undergoing corneal transplantation has decreased and DMEK is performed in a wide range of FECD stages. Currently, surgical indications are based mainly on best-corrected visual acuity, central corneal thickness, and patients ’ subjective symptoms.
Source: JAMA Ophthalmology - Category: Opthalmology Source Type: research